The National Science Foundation (NSF) has awarded Third Eye Diagnostics, Inc. $500,000 to advance development of the CerePress™, a non-invasive, handheld intracranial pressure (ICP) monitor. The CerePress™ is targeted for use in combat theaters, hospital ER's, medical transport vehicles, and sports events (e.g., NFL, NHL, college and high school athletics) for the rapid diagnosis of brain injury.
In a small clinical study, researchers administered a new method for treating chronic wounds using a novel ultrasound applicator that can be worn like a band-aid. The applicator delivers low-frequency, low-intensity ultrasound directly to wounds, and was found to significantly accelerate healing in five patients with venous ulcers.
Three quarters of the population of China and India are diabetic. This translates to a patient pool of nearly 200 million for the self monitoring of blood glucose (SMBG) market. However, not more than 45 percent of these patients have been diagnosed, which represents a vast underserved market.
Research and Markets has announced the addition of the "Global Blood Pressure Monitor Market 2012-2016" report to their offering.
Researchers from the University of Liverpool and University of the West of England, (UWE Bristol), have built a device that can read odours in urine to help diagnose patients with early signs of bladder cancer.
Blood Cell Storage, Inc. (BCSI), a leading medical device provider based in Seattle, WA and ORIGIO a/s, a leader in delivering innovative Assisted Reproductive Technology solutions headquartered in Malov Denmark, announced a partnership today during the annual meeting of the European Society of Human Reproduction and Embryology (ESHRE).
Flexpoint Sensor Systems, Inc., today announced that following the recently announced favorable universal settlement in the legal case involving a series of products featuring technologies that use Bend Sensor® technology, Flexpoint has resumed development of two projects with BendTech, LLC, which feature Flexpoints' Patented Bend Sensor® technology.
Qardio, a healthcare technology company, today unveils two revolutionary, cardiovascular monitoring devices. QardioCore and QardioArm are elegantly designed for effortless daily-wear, continuous monitoring by those with, or at risk of developing, cardiovascular conditions, and sharing with physicians or loved ones.
JDRF and BD (Becton, Dickinson and Company) are accelerating the development of new products that combine BD’s proprietary insulin infusion and glucose sensing technologies through a new collaboration announced today. This new, three-year commitment is an extension of existing JDRF-BD collaborations focused on type 1 diabetes (T1D).
New technology under development at The Ohio State University is paving the way for low-cost electronic devices that work in direct contact with living tissue inside the body.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.